MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and
MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and pelvis. The agent last month completedphase-three clinical trials and Pharmacyclics plans to submita new drug application in the middle of this year.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study: Black Patients Less Likely Than Others to Receive MRI Assessment of Cognitive Impairment
November 27th 2023In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.